Used in pharmaceutical research as a potent inhibitor of Janus kinase (JAK) enzymes, particularly JAK1 and JAK3. It shows promise in the development of treatments for autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease due to its ability to modulate immune signaling pathways. Its acrylamide group enables covalent binding to cysteine residues in target kinases, enhancing selectivity and prolonging inhibitory effects. Also serves as a lead compound in the design of irreversible kinase inhibitors for oncology and chronic inflammatory conditions.